199 related articles for article (PubMed ID: 12207785)
1. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules.
Beesley MF; McLaren KM
Histopathology; 2002 Sep; 41(3):236-43. PubMed ID: 12207785
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
de Matos PS; Ferreira AP; de Oliveira Facuri F; Assumpção LV; Metze K; Ward LS
Histopathology; 2005 Oct; 47(4):391-401. PubMed ID: 16178894
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
Abd-El Raouf SM; Ibrahim TR
Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
[TBL] [Abstract][Full Text] [Related]
4. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW
Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
[TBL] [Abstract][Full Text] [Related]
5. Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma.
Tan A; Etit D; Bayol U; Altinel D; Tan S
Ann Diagn Pathol; 2011 Apr; 15(2):108-16. PubMed ID: 21315633
[TBL] [Abstract][Full Text] [Related]
6. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms.
Inohara H; Honjo Y; Yoshii T; Akahani S; Yoshida J; Hattori K; Okamoto S; Sawada T; Raz A; Kubo T
Cancer; 1999 Jun; 85(11):2475-84. PubMed ID: 10357421
[TBL] [Abstract][Full Text] [Related]
7. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
Teng XD; Wang LJ; Yao HT; Li J; Ding W; Yan LP
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.
Park YJ; Kwak SH; Kim DC; Kim H; Choe G; Park DJ; Jang HC; Park SH; Cho BY; Park SY
J Korean Med Sci; 2007 Aug; 22(4):621-8. PubMed ID: 17728499
[TBL] [Abstract][Full Text] [Related]
9. Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia.
Coli A; Bigotti G; Zucchetti F; Negro F; Massi G
Histopathology; 2002 Jan; 40(1):80-7. PubMed ID: 11903601
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of galectin-3 in aspirates of thyroid follicular lesions.
Kim MJ; Kim HJ; Hong SJ; Shong YK; Gong G
Acta Cytol; 2006; 50(1):28-34. PubMed ID: 16514837
[TBL] [Abstract][Full Text] [Related]
11. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas.
Saggiorato E; Aversa S; Deandreis D; Arecco F; Mussa A; Puligheddu B; Cappia S; Conticello S; Papotti M; Orlandi F
J Endocrinol Invest; 2004 Apr; 27(4):311-7. PubMed ID: 15233548
[TBL] [Abstract][Full Text] [Related]
12. Immune characterization of thyroid neoplasm's and its variants using immunohistochemical markers: CK-19, Galectin-3 and Hector Battifora mesothelial-1.
Nehal S; Mittal R; Misra P; Rath J; Senapati U
Ann Diagn Pathol; 2022 Jun; 58():151931. PubMed ID: 35255428
[TBL] [Abstract][Full Text] [Related]
13. [Significance of galectin-3 and CD44v6 expression in differential diagnosis of thyroid nodules].
Wang LH; Zhao YJ; Wang XY; Yuan P; Xu WQ; Xiao JC; Xu JP; Luo BR
Zhonghua Zhong Liu Za Zhi; 2005 Sep; 27(9):547-50. PubMed ID: 16438854
[TBL] [Abstract][Full Text] [Related]
14. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue.
Fernández PL; Merino MJ; Gómez M; Campo E; Medina T; Castronovo V; Sanjuán X; Cardesa A; Liu FT; Sobel ME
J Pathol; 1997 Jan; 181(1):80-6. PubMed ID: 9072007
[TBL] [Abstract][Full Text] [Related]
15. [Cytokeratin expression of benign and malignant epithelial thyroid gland tumors. An immunohistologic study of 154 neoplasms using 8 different monoclonal cytokeratin antibodies].
Schröder S; Wodzynski A; Padberg B
Pathologe; 1996 Nov; 17(6):425-32. PubMed ID: 9082363
[TBL] [Abstract][Full Text] [Related]
16. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
Mataraci EA; Ozgüven BY; Kabukçuoglu F
Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of galectin-3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules.
Aratake Y; Umeki K; Kiyoyama K; Hinoura Y; Sato S; Ohno A; Kuribayashi T; Hirai K; Nabeshima K; Kotani T
Diagn Cytopathol; 2002 Jun; 26(6):366-72. PubMed ID: 12112826
[TBL] [Abstract][Full Text] [Related]
18. High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors.
Raphael SJ; McKeown-Eyssen G; Asa SL
Mod Pathol; 1994 Apr; 7(3):295-300. PubMed ID: 7520169
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma.
Jakubiak-Wielganowicz M; Kubiak R; Sygut J; Pomorski L; Kordek R
Pol J Pathol; 2003; 54(2):111-5. PubMed ID: 14575419
[TBL] [Abstract][Full Text] [Related]
20. Keratin subsets in papillary and follicular thyroid lesions. A paraffin section analysis with diagnostic implications.
Miettinen M; Kovatich AJ; Kärkkäinen P
Virchows Arch; 1997 Dec; 431(6):407-13. PubMed ID: 9428928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
